SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/12/20 Amgen Inc 10-K 12/31/19 153:23M |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 2.77M 2: EX-2.3 Amendment to No. 2 to the Asset Purchase Agreement HTML 50K Between Amgen and Celgene 3: EX-2.4 Letter Agreement - Treatment of Certain Product HTML 244K Inventory 4: EX-4.29 Description of Securities HTML 166K 9: EX-10.10 Form of Restricted Stock Unit Agreement HTML 67K 10: EX-10.11 Form of Cash-Settled Restricted Stock Unit HTML 65K Agreement 11: EX-10.14 Second Amendment to Supplemental Retirement Plan HTML 41K 12: EX-10.21 Second Amendment to Nonqualified Deferred HTML 41K Compensation Plan 5: EX-10.4 Form of Grant of Stock Option Agreement HTML 213K 13: EX-10.41 Collaboration Agreement HTML 466K 14: EX-10.42 Guarantee Agreement HTML 71K 6: EX-10.5 Form of Restricted Stock Unit Agreement HTML 211K 7: EX-10.7 Form of Performance Unit Agreement HTML 202K 8: EX-10.8 Director Equity Incentive Program HTML 69K 15: EX-21 Subsidiaries of the Company HTML 45K 16: EX-31 Rule 13A-14(A) Certifications HTML 54K 17: EX-32 Section 1350 Certifications HTML 43K 101: R1 Cover page HTML 112K 54: R2 Consolidated Statements of Income HTML 101K 71: R3 Consolidated Statements of Comprehensive Income HTML 64K 150: R4 Consolidated Balance Sheets HTML 117K 99: R5 Consolidated Balance Sheets (Parenthetical) HTML 45K 53: R6 Consolidated Statements of Stockholders' Equity HTML 91K 70: R7 Consolidated Statements of Stockholders' Equity HTML 41K (Parenthetical) 148: R8 Consolidated Statements of Cash Flows HTML 120K 103: R9 Summary of significant accounting policies HTML 74K 149: R10 Acquisitions HTML 75K 104: R11 Revenues HTML 160K 52: R12 Stock-based compensation HTML 135K 73: R13 Defined contribution plan HTML 41K 147: R14 Income taxes HTML 155K 102: R15 Earnings per share HTML 63K 51: R16 Collaborations HTML 58K 72: R17 Investments HTML 197K 151: R18 Inventories HTML 48K 100: R19 Property, plant and equipment HTML 71K 25: R20 Goodwill and intangible assets HTML 96K 75: R21 Leases HTML 81K 124: R22 Other current assets and accrued liabilities HTML 60K 110: R23 Financing arrangements HTML 154K 24: R24 Stockholders' equity HTML 181K 74: R25 Fair value measurement HTML 220K 123: R26 Derivative instruments HTML 237K 109: R27 Contingencies and commitments HTML 172K 23: R28 Quarterly financial data (Unaudited) HTML 83K 76: R29 Subsequent events HTML 43K 68: R30 Schedule Ii - Valuation and Qualifying Accounts HTML 59K 48: R31 Summary of significant accounting policies - HTML 139K (Policies) 106: R32 Acquisitions - (Tables) HTML 63K 152: R33 Revenues (Tables) HTML 159K 69: R34 Stock-based compensation (Tables) HTML 128K 49: R35 Income taxes (Tables) HTML 153K 107: R36 Earnings per share (Tables) HTML 62K 153: R37 Investments - (Tables) HTML 192K 67: R38 Inventories (Tables) HTML 50K 50: R39 Property, plant and equipment (Tables) HTML 73K 85: R40 Goodwill and other intangible assets - (Tables) HTML 93K 33: R41 Leases - (Tables) HTML 81K 111: R42 Other current assets and accrued liabilities HTML 63K (Tables) 125: R43 Financing arrangements (Tables) HTML 141K 86: R44 Stockholders' equity (Tables) HTML 177K 34: R45 Fair value measurement - (Tables) HTML 201K 112: R46 Derivative instruments - (Tables) HTML 230K 126: R47 Contingencies and commitments - (Tables) HTML 46K 84: R48 Quarterly financial data (Unaudited) (Tables) HTML 82K 36: R49 Summary of significant accounting policies - HTML 61K Narrative (Details) 46: R50 Acquisitions - Narrative (Details) HTML 106K 65: R51 Acquisitions - Otezla (Details) HTML 62K 138: R52 Acquisitions - Aggregate Consideration Paid HTML 62K (Details) 89: R53 Revenues - Narrative (Details) HTML 164K 45: R54 Revenues - Customer Concentration, Product Sales HTML 60K (Details) 63: R55 Stock-based compensation (Textual) (Details) HTML 97K 135: R56 Stock-based compensation (Components of HTML 51K Stock-based Compensation Expense) (Details) 88: R57 Stock-based compensation (Summary of RSUs) HTML 65K (Details) 44: R58 Stock-based compensation Stock-based compensation HTML 56K (Summary of Stock Options) (Details) 66: R59 Stock-based compensation (Summary of Stock HTML 92K Options) (Details) 130: R60 Stock-based compensation (Weighted-average HTML 50K Assumptions) (Details) 119: R61 Defined contribution plan (Details) HTML 40K 30: R62 Income taxes (Income Before Income Taxes) HTML 46K (Details) 81: R63 Income taxes (Provision for Income Taxes) HTML 69K (Details) 129: R64 Income taxes (Components of Deferred Tax Assets HTML 78K and Liabilities) (Details) 116: R65 Income taxes (Textual) (Details) HTML 74K 27: R66 Income taxes (Reconciliation of Total Gross HTML 54K Amounts of UTBs) (Details) 80: R67 Income taxes (Reconciliation of Federal Statutory HTML 74K Tax Rate) (Details) 133: R68 Earnings per share (Details) HTML 68K 113: R69 Collaborations - Novartis AG (Details) HTML 63K 93: R70 Collaborations - Bayer HealthCare Pharmaceuticals HTML 57K Inc. (Details) 142: R71 Investments - Schedule (Details) HTML 84K 56: R72 Investments - Fair Values by Classification HTML 51K (Details) 40: R73 Investments - Available-for-sale (Details) HTML 46K 94: R74 Investments - Fair Values by Contractual Maturity HTML 55K (Details) 145: R75 Investments - Unrealized Losses and Fair Values HTML 83K (Details) 59: R76 Investments - Equity Securities (Details) HTML 42K 41: R77 Investments - Limited Partnership Investments HTML 44K (Details) 98: R78 Inventories (Details) HTML 50K 140: R79 Property, plant and equipment (Schedule) (Details) HTML 90K 91: R80 Property, plant and equipment (Geographic HTML 48K Information) (Details) 141: R81 Goodwill and other intangible assets - Goodwill HTML 46K Roll Forward (Details) 55: R82 Goodwill and other intangible assets - HTML 69K Identifiable Intangible Assets (Details) 38: R83 Goodwill and other intangible assets - Narrative HTML 55K (Details) 96: R84 Leases - Narrative (Details) HTML 63K 146: R85 Leases - Summary of Leases (Details) HTML 47K 60: R86 Leases - Components of Lease Costs (Details) HTML 45K 43: R87 Maturities of Lease Liabilities (Details) HTML 62K 97: R88 Leases - Cash and Noncash Information of Leases HTML 43K (Details) 139: R89 Leases - Prior to adoption (Details) HTML 59K 132: R90 Other current assets and accrued liabilities HTML 49K Schedule of Other Assets (Details) 120: R91 Schedule of Accrued Liabilities (Details) HTML 53K 31: R92 Financing arrangements (Principal Amounts and HTML 242K Carrying Value of Long-term Borrowings) (Details) 83: R93 Financing arrangements (Debt Issuances) (Details) HTML 61K 127: R94 Financing arrangements (Debt Repayments) (Details) HTML 78K 115: R95 Financing arrangements (Interest Rate and HTML 91K Cross-currency Swaps) (Details) 26: R96 Financing arrangements (Shelf Registration HTML 65K Statements and Other Facilities) (Details) 78: R97 Financing arrangements (Contractual Maturities of HTML 58K Long-term Debt) (Details) 134: R98 Financing arrangements (Interest Costs) (Details) HTML 41K 114: R99 Stockholders' equity (Stock Repurchase Program) HTML 55K (Details) 39: R100 Stockholders' equity (Dividends) (Details) HTML 47K 57: R101 Stockholders' equity (Components of AOCI) HTML 81K (Details) 143: R102 Stockholders' equity (Accumulated Other HTML 50K Comprehensive Income (Loss), Textual) (Details) 92: R103 Stockholders' equity (Reclassifications out of HTML 93K AOCI) (Details) 42: R104 Stockholders' equity (Other) (Details) HTML 47K 58: R105 Fair value measurement - (Fair Value of Financial HTML 160K Assets and Liabilities on Recurring Basis) (Details) 144: R106 Fair value measurement - Narrative (Details) HTML 75K 95: R107 Derivative instruments - Narrative (Details) HTML 60K 37: R108 Derivative instruments - (Cross-currency Swaps) HTML 73K (Details) 62: R109 Derivative instruments - (Effective Portion of HTML 50K Unrealized Gain (Loss)) (Details) 82: R110 Derivative instruments - (Hedged Liabilities and HTML 52K Cumulative Amount) (Details) (Details) 29: R111 Derivative instruments - (Summary of Income and HTML 72K Expense Line Items) (Details) 118: R112 Derivative instruments - (Fair Value of HTML 71K Derivatives) (Details) 131: R113 Contingencies and commitments (Sensipar ANDA HTML 45K Patent Litigation) (Details) 79: R114 Contingencies and commitments (Sandoz Patent HTML 47K Litigation) (Details) 28: R115 Contingencies and commitments (Repatha Patent HTML 46K Litigation) (Details) 117: R116 Contingencies and commitments (NEUPOGEN Patent HTML 45K Litigation) (Details) 128: R117 Contingencies and commitments (EPOGEN Patent HTML 47K Litigation) (Details) 77: R118 Contingencies and commitments (AMJEVITA Patent HTML 41K Litigation) (Details) 32: R119 Contingencies and commitments (KANJINTI Patent HTML 42K Litigation) (Details) 90: R120 Contingencies and commitments (MVASI Patent HTML 46K Litigation) (Details) 137: R121 Contingencies and commitments (Additional HTML 53K Information) (Details) 64: R122 Contingencies and commitments (U.S. Repatriation HTML 55K Tax Commitments) (Details) 47: R123 Quarterly financial data (Unaudited) (Details) HTML 68K 87: R124 Subsequent events - Narrative (Details) HTML 50K 136: R125 Schedule Ii - Valuation and Qualifying Accounts HTML 48K (Details) 108: R9999 Uncategorized Items - amgn-12312019x10kq42019.htm HTML 39K 35: XML IDEA XML File -- Filing Summary XML 278K 122: XML XBRL Instance -- amgn-12312019x10kq42019_htm XML 5.74M 105: EXCEL IDEA Workbook of Financial Reports XLSX 175K 19: EX-101.CAL XBRL Calculations -- amgn-20191231_cal XML 375K 20: EX-101.DEF XBRL Definitions -- amgn-20191231_def XML 1.36M 21: EX-101.LAB XBRL Labels -- amgn-20191231_lab XML 2.86M 22: EX-101.PRE XBRL Presentations -- amgn-20191231_pre XML 1.85M 18: EX-101.SCH XBRL Schema -- amgn-20191231 XSD 319K 121: JSON XBRL Instance as JSON Data -- MetaLinks 591± 892K 61: ZIP XBRL Zipped Folder -- 0000318154-20-000017-xbrl Zip 1.06M
Exhibit |
1. | Section 3.1(d) is deleted in its entirety. |
2. | Section
8.5 is amended by deleting the fourth sentence thereof and replacing it with the following: |
By: | /s/
Lori A. Johnston |
Name: Lori A. Johnston Title: Executive Vice President, Human Resources |
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 2/12/20 | 4, SC 13G/A | ||
1/1/20 | 3 | |||
For Period end: | 12/31/19 | 10-K/A, 11-K | ||
10/16/13 | 3, 8-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/03/24 Amgen Inc. 10-Q 3/31/24 81:8.5M 2/14/24 Amgen Inc. 10-K 12/31/23 159:22M 10/31/23 Amgen Inc. 10-Q 9/30/23 85:10M 8/04/23 Amgen Inc. 10-Q 6/30/23 86:10M 4/28/23 Amgen Inc. 10-Q 3/31/23 82:9.6M 2/09/23 Amgen Inc. 10-K 12/31/22 144:21M 11/04/22 Amgen Inc. 10-Q 9/30/22 81:10M 8/05/22 Amgen Inc. 10-Q 6/30/22 82:12M 4/28/22 Amgen Inc. 10-Q 3/31/22 77:9M 2/16/22 Amgen Inc. 10-K 12/31/21 139:19M 11/03/21 Amgen Inc. S-8 11/03/21 4:77K Donnelley … Solutions/FA 11/03/21 Amgen Inc. 10-Q 9/30/21 80:11M 8/04/21 Amgen Inc. 10-Q 6/30/21 79:11M 4/28/21 Amgen Inc. 10-Q 3/31/21 74:8.3M 2/09/21 Amgen Inc. 10-K 12/31/20 140:20M 10/29/20 Amgen Inc. 10-Q 9/30/20 78:11M |